Piper Sandler Maintains Overweight on Conmed, Lowers Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien maintains an Overweight rating on Conmed (NYSE:CNMD) but lowers the price target from $95 to $80.
August 01, 2024 | 3:50 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler analyst Matt O'Brien maintains an Overweight rating on Conmed but lowers the price target from $95 to $80.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100